Key Takeaways
- • Goldman Sachs and Jefferies are leading a €1.5bn ($1.75bn) financing package for Lone Star Funds' acquisition of Lonza Group AG's capsules and health ingredients business, with early-stage investor soundings underway ahead of wider syndication this quarter.
- • The debt structure comprises approximately €1bn in leveraged loans and €500m in high-yield bonds, designed to appeal to distinct investor pools across Europe's leveraged finance market.
- • Lone Star agreed last month to acquire the unit for CHF2.3bn ($2.9bn), with Lonza receiving CHF1.7bn in cash upfront while retaining a 40% equity stake in the business.
- • An 11-bank syndicate including UBS, BBVA, BNP Paribas, ING, Société Générale, Standard Chartered, UniCredit, Intesa Sanpaolo, and Raiffeisen Bank International is participating in the financing arrangement.
- • The underlying asset—a pharmaceutical and biotech-focused capsules and health ingredients division—is positioned as a defensive industrial asset, expected to attract investor interest amid broader leveraged credit market scrutiny of higher-risk software borrowers.
Summary
Goldman Sachs and Jefferies Financial Group have commenced investor soundings for a €1.5bn financing package supporting Lone Star Funds' acquisition of Lonza Group AG's capsules and health ingredients business. The banks are conducting early-stage discussions with a select group of investors before launching wider syndication expected later in the second quarter. This initial approach represents standard practice in large-cap leveraged finance transactions, allowing lead arrangers to gauge market appetite and refine terms prior to a formal marketing roadshow.
The financing package is structured in two tranches to optimize appeal across Europe's institutional investor base. Approximately €1bn will be raised through leveraged loans, targeting traditional bank and credit fund investors, while €500m will be raised via high-yield bonds, targeting broader fixed-income portfolios. This bifurcated approach allows Lone Star to access both loan and bond markets simultaneously, diversifying its funding sources and potentially reducing execution risk.
The underlying transaction values Lonza's capsules and health ingredients unit at CHF2.3bn ($2.9bn). Under the acquisition structure agreed last month, Lonza will receive CHF1.7bn in cash upfront from Lone Star while maintaining a 40% equity stake in the business. This arrangement signals confidence from the seller and aligns incentives between the new owner and existing management, a structure that typically supports post-acquisition operational continuity.
An extensive banking syndicate of 11 institutions has been assembled to support the financing, including UBS, BBVA, BNP Paribas, ING, Société Générale, Standard Chartered, UniCredit, Intesa Sanpaolo, and Raiffeisen Bank International. The broad syndicate distribution reflects the transaction size and underscores lead banks' confidence in market demand.
Market timing appears favorable for the deal launch. European syndicated loan and bond markets have demonstrated tentative reopening after recent volatility linked to geopolitical tensions. Additionally, the capsules and health ingredients business is positioned as a defensive industrial asset within the pharmaceutical and biotech sectors, offering relative stability compared to higher-risk technology and software borrowers that have faced increased leveraged credit market scrutiny. This asset-class positioning should support institutional investor interest during the upcoming syndication phase.
The financing package is structured in two tranches to optimize appeal across Europe's institutional investor base. Approximately €1bn will be raised through leveraged loans, targeting traditional bank and credit fund investors, while €500m will be raised via high-yield bonds, targeting broader fixed-income portfolios. This bifurcated approach allows Lone Star to access both loan and bond markets simultaneously, diversifying its funding sources and potentially reducing execution risk.
The underlying transaction values Lonza's capsules and health ingredients unit at CHF2.3bn ($2.9bn). Under the acquisition structure agreed last month, Lonza will receive CHF1.7bn in cash upfront from Lone Star while maintaining a 40% equity stake in the business. This arrangement signals confidence from the seller and aligns incentives between the new owner and existing management, a structure that typically supports post-acquisition operational continuity.
An extensive banking syndicate of 11 institutions has been assembled to support the financing, including UBS, BBVA, BNP Paribas, ING, Société Générale, Standard Chartered, UniCredit, Intesa Sanpaolo, and Raiffeisen Bank International. The broad syndicate distribution reflects the transaction size and underscores lead banks' confidence in market demand.
Market timing appears favorable for the deal launch. European syndicated loan and bond markets have demonstrated tentative reopening after recent volatility linked to geopolitical tensions. Additionally, the capsules and health ingredients business is positioned as a defensive industrial asset within the pharmaceutical and biotech sectors, offering relative stability compared to higher-risk technology and software borrowers that have faced increased leveraged credit market scrutiny. This asset-class positioning should support institutional investor interest during the upcoming syndication phase.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.